Abstract: It is indisputable that epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) prolong progression-free survival in non-small-cell lung cancer (NSCLC) patients with EGFR mutations better than cytotoxic chemotherapy. However, it is unclear whether EGFR-TKIs prolong the overall survival of NSCLC patients, especially in those with postsurgical recurrence. We retrospectively examined 304 NSCLC patients with known EGFR mutational status (excluding those with squamous cell carcinoma), who had undergone pulmonary resection and experienced postsurgical recurrence. Of these patients, 137 carried EGFR mutations and 167 did not. Of the 137 patients with EGFR mutations, 83 were treated with EGFR-TKIs for their recurrent disease, and 32 of the 167 patients without EGFR mutations were treated with EGFR-TKIs. Postsurgical survival was divided into two parts: recurrence-free survival (RFS) and postrecurrence survival (PRS), and these were compared between the subgroups with a multivariate analysis, adjusted for baseline clinical characteristics. There was no significant difference in RFS between patients with EGFR mutations and those without (P = 0.88). PRS was also similar in these two subgroups when we excluded patients who had been treated with EGFR-TKIs (P = 0.64). In patients with EGFR mutations, PRS was significantly longer in those who were treated with EGFR-TKIs than in those who were not given EGFR-TKIs (P = 0.04). However, among patients without EGFR mutations, PRS was similar in patients who had and had not been treated with EGFR-TKIs (P = 0.87). In conclusion, among NSCLC patients with postsurgical recurrence, EGFR-TKIs prolonged PRS in those with EGFR mutations.
INTRODUCTION
Preclinical and clinical studies have shown that nonsmall-cell lung cancers (NSCLCs) with epidermal growth factor receptor gene (EGFR) mutations are exquisitely sensitive to orally available EGFR tyrosine kinase inhibitors (EGFR-TKIs; gefitinib and erlotinib) [1] [2] [3] . Four recent phase III trials have shown that the progression-free survival (PFS) of patients with advanced NSCLC treated with these EGFR-TKIs was longer than that of patients treated with platinum-based chemotherapy when the patients had EGFR mutations [4] [5] [6] [7] .
However, in the WJTOG3405 study, which included a large number of patients with postsurgical recurrence (n = 71; 41%), postsurgical recurrence itself was a better prognostic factor than stage IIIB/IV disease (hazards ratio [HR] 0.433, P < 0.0001) [4] . In the subgroup analysis of the WJTOG3405 study, PFS was *Address corresponding to this author at the Division of Thoracic Surgery, Department of Surgery, Kinki University Faculty of Medicine, 377-2 OhnoHigashi, Osaka-Sayama, Japan; Tel: +81 72 (366) 0221; Fax: +81 72 (367) 7771; E-mail: mitsudom@surg.med.kindai.ac.jp significantly longer in the gefitinib group than in the chemotherapy group of patients with stage IIIB/IV disease (n = 101; median PFS, 8.4 vs 5.4 months, respectively; P < 0.0001), but this difference was not statistically significant in patients with postsurgical recurrence (n = 71; median PFS, 13.7 vs 8.1 months, respectively; P = 0.069). The PFS curves for the two subgroups also differed: the curves for the gefitinib and chemotherapy groups in the postsurgical recurrence subgroup overlapped during the first six months, whereas the curves for the stage IIIB/IV subgroup were clearly separated during this period. These results indicate that the baseline characteristics and response to treatment of NSCLC patients with postsurgical recurrence may differ from those with advanced disease.
Overall survival (OS), rather than PFS, has been regarded as the gold standard measure for evaluating the clinical benefit of antitumor therapies. The NEJ002 and WJTOG3405 studies both failed to show the clinical benefit of gefitinib on overall survival [4, 8] , probably because of the high crossover rate. To establish whether EGFR-TKIs improve OS in NSCLC patients, Takano et al. performed a historical comparison of lung adenocarcinoma patients treated before and after gefitinib approval in Japan [9] . They demonstrated that OS was significantly longer among EGFR-mutant patients treated after gefitinib approval compared with those treated before it, whereas no improvement in survival was observed in patients without EGFR mutations. However, their patient cohort consisted predominantly of patients with advanced lung adenocarcinomas (76% and 59% of patients treated before and after gefitinib approval, respectively), rather than those with postsurgical recurrence.
Therefore, it remains unclear whether EGFR-TKIs can prolong OS in NSCLC patients with postsurgical recurrence. To address this question, we performed a retrospective analysis of NSCLC patients with a known EGFR mutational status, comparing those who were treated with EGFR-TKIs and those who were not.
PATIENTS AND METHODS

Study Population and Procedures
We analyzed 375 Japanese NSCLC patients (excluding those with squamous cell carcinoma) who had undergone pulmonary resection at the Department of Thoracic Surgery, Aichi Cancer Center Hospital, between May 2000 and December 2008, and who had experienced a recurrence by September 2011. All the patients gave their written informed consent to their participation and the appropriate approval was obtained in advance from our institutional review board.
In this cohort, samples from 304 patients were available for EGFR mutational analysis and those patients were included in the study. Complete clinical data including sex, age, pathological diagnosis, pathological stage (7 th edition), date of surgery, date of relapse, date of death were obtained from medical records and reviewed by the physicians. EGFR mutational analysis was performed as previously reported [10] . EGFR mutations were detected in 137 patients, and 83 of those patients were treated with EGFR-TKI monotherapy (gefitinib, 65 patients; erlotinib, six patients; and both, 12 patients) at any line of the treatment. Of the 167 patients without EGFR mutations, 32 were treated with EGFR-TKI monotherapy (gefitinib, 27 patients; erlotinib, five patients). Further details of the clinical and pathological characteristics of the patients are shown in Table 1 . No significant clinicopathological differences were observed between the patients who were or were not treated with EGFR-TKIs in both the mutant EGFR and wild-type EGFR subgroups.
Clinical Outcomes and Statistical Analysis
Postsurgical survival was divided into two parts: postsurgical recurrence-free survival (RFS) and postrecurrence survival (PRS). RFS was defined as the time from pulmonary resection to the detection of recurrence. PRS was defined as the time from the recognition of recurrence to death. Patients without a known date of death were censored at the time of the last follow-up. Significance was set at P < 0.05.
RESULTS
No Significant Differences in RFS between Subgroups
We first compared the RFS of patients with and without EGFR mutations, and identified no significant difference (HR = 0.98; 95% confidence interval [CI], 0.76-1.27; P = 0.88).
We then compared the RFS of patients treated with and without EGFR-TKIs to confirm that the baseline potential of these two subgroups was similar. In both patients with and those without EGFR mutations, we observed no significant difference in RFS between those who had been treated with EGFR-TKIs and those who had not, i.e., HR for EGFR-TKI-treated patients was 1.05 in patients with EGFR mutations (P = 0.78; Table 2 ) and 1.19 in those without EGFR mutations (P = 0.43; Table 3 ).
Treatment with EGFR-TKIs Prolonged PRS in Patients with EGFR Mutations But Not in Those without EGFR Mutations
We compared the PRS of the subgroups. In the analysis of all 304 patients, the patients with EGFR mutations survived longer than those without EGFR mutations (HR = 0.63; 95% CI, 0.47-0.86; P < 0.01).
To examine the effect of EGFR-TKIs on PRS, we divided the patients into those with EGFR mutations and those without EGFR mutations, because the efficacy of these drugs is strongly influenced by the presence of EGFR mutations. In patients with EGFR mutations, PRS was significantly longer in those who had been treated with EGFR-TKIs (HR = 0.60; 95% CI, 0.36-0.97; P = 0.04; Table 2 ). In contrast, in patients without EGFR mutations, PRS was similar in patients who had been treated with EGFR-TKIs and those who had not (HR = 0.96; 95% CI, 0.62-1.49; P = 0.87; Table 3 ). 
PRS Was Similar in Patients with and without EGFR Mutations in the Absence of EGFR-TKIs
Our results indicated that EGFR-TKIs prolonged PRS in patients with EGFR mutations but not in those without EGFR mutations. To determine whether patients with EGFR mutations live longer than those without EGFR mutations, even in the absence of EGFR-TKIs, we excluded patients who had been treated with EGFR-TKIs. The analysis of 189 patients (54 patients with and 135 patients without EGFR mutations) showed that RFS was similar in both subgroups (HR for patients with EGFR mutations was 0.92; 95% CI, 0.63-1.33; P = 0.64). PRS was also similar in these two subgroups (HR for patients with EGFR mutations was 0.89; 95% CI, 0.56-1.41; P = 0.62).
DISCUSSION
In this study, we identified two important trends in NSCLC patients with postsurgical recurrence. First, EGFR mutational status was not a prognostic factor in patients with postsurgical recurrence. This finding is based on two results: i) RFS was similar in patients with and without EGFR mutations; and ii) PRS was also similar in these two subgroups if we excluded patients who had been treated with EGFR-TKIs. This is consistent with several retrospective analyses of patients with early-stage NSCLC, which have shown that the presence of EGFR mutations was associated with a favorable prognosis for OS in univariate analyses but not after adjustments were made for the patients' backgrounds [10] [11] [12] . For instance, in our previous analysis of lung adenocarcinoma patients who had undergone potentially curative pulmonary resection, disease stage (P < 0.0001) and smoking status (P = 0.0310) were independent prognostic factors for postsurgical survival, but the mutational status of any gene was not (EGFR, P = 0.3225; KRAS, P = 0.8500; TP53, P = 0.3191) [10] .
Another finding of this study was that the PRS of NSCLC patients with EGFR mutations was significantly longer in patients who were given EGFR-TKIs than in those who were not. This result may have been considered as a foregone conclusion, but our analysis is important in establishing the ultimate clinical benefit of EGFR-TKIs in patients with EGFR mutations who experience postsurgical recurrence.
The PRS of NSCLC patients without EGFR mutations was similar in patients who were and were 14] , whereas no such data have been reported for gefitinib. In our cohort, only five of the 167 NSCLC patients without EGFR mutations had received erlotinib. Analysis of a larger sample of patients treated with erlotinib may conclude whether NSCLC patients without EGFR mutations will benefit from EGFR-TKIs or not.
The present study was our second attempt to establish the clinical benefit of EGFR-TKIs on OS in patients who experienced postsurgical recurrence. We previously compared 81 patients who had been treated with gefitinib with 81 patients matched for sex, age, pathological stage, and smoking status who were not given EGFR-TKIs [15] . In that study, we used a matching method to exclude selection bias for EGFR-TKI treatment, but that method yielded a small patient sample and an uneven distribution of EGFR mutational status across the treatment groups. Therefore, in this study, we analyzed a large number of patients, dividing these patients according to their EGFR mutational status, and clearly identified the clinical benefit of EGFR-TKIs in NSCLC patients with EGFR mutations but not in those without EGFR mutations.
In conclusion, our results indicate that the presence of EGFR mutations is not a prognostic factor for NSCLC patients with postsurgical recurrence. However, EGFR-TKIs prolonged PRS in NSCLC patients with EGFR mutations, but not in those without EGFR mutations.
